Can Kailera become the next major GLP-1 challenger after pricing one of biotech’s biggest IPOs in years?
UCB SA (EBR: UCB) bets $1.15 bn on Neurona Therapeutics to push epilepsy treatment beyond symptom control
Read More General news updates Can Sam Konstas be Australia’s next cricketing mainstay? Sam Konstas, a prodigious 19-year-old cricketer from New South Wales, has captured national and global attention with his… byPallavi MadhirajuJanuary 4, 2025